Otsuka Holdings Co., Ltd.
[Otsuka Holdings] Favorable Results in Phase 3 Trial of IgA Nephropathy Drug | June 2026
Otsuka Pharmaceutical's subsidiary has announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab, demonstrating renal function preservation and progressing with approval application to the US FDA. There are no changes to the consolidated performance forecast for the fiscal year ending December 2026.
Key Figures
- eGFR change (12 months): +0.7 mL/min/1.73 m²
- Treatment Effect Difference: 5.5 mL/min/1.73 m²
- eGFR slope (annual change rate): −3.0 mL/min/1.73 m²/year
AI要約
Performance Overview
Otsuka Pharmaceutical's subsidiary announced interim analysis results of the Phase 3 trial for the IgA nephropathy treatment drug cebepraelimab. The trial successfully maintained eGFR over 12 months, demonstrating therapeutic effect. Subsequently, renewal applications are being progressively submitted to the US FDA. The results suggest potential for renal function decline suppression, raising expectations for long-term prognosis improvement. There are no changes to the consolidated performance forecast for the fiscal year ending December 2026.
Future Outlook and Investor Impact
In response to favorable interim analysis results, preparations are underway for formal approval of cebepraelimab. Acquisition of long-term clinical data and approval in the US market are expected to enable revenue generation and business expansion for this treatment. Safety profiles are also favorable, and the final results of future clinical trials are anticipated to further contribute to long-term prognosis improvements.
Otsuka Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
